Literature DB >> 30142417

Bone Marrow versus Peripheral Blood from Unrelated Donors for Children and Adolescents with Acute Leukemia.

Daniel A Keesler1, Andrew St Martin1, Carmem Bonfim2, Adriana Seber3, Mei-Jie Zhang4, Mary Eapen5.   

Abstract

Graft-versus-host disease (GVHD) rates are higher after unrelated donor transplantation; thus, we examined whether there would be differences in transplant outcomes by graft type in children and adolescents with acute leukemia. The primary endpoint was overall survival. We studied 872 patients <18 years old who were transplanted with bone marrow (n = 650) or peripheral blood (n = 222) from unrelated donors. The characteristics of the 2 groups were comparable, except recipients of bone marrow were younger than recipients of peripheral blood (median age, 10 versus 12 years). Grades 2 to 4 (hazard ratio [HR], 1.48; P < .001) and grades 3 and 4 acute (HR, 1.69; P < .001) and chronic GVHD (HR, 1.92; P < .001) were higher with transplantation of peripheral blood than with bone marrow. Although relapse risks were lower after peripheral blood transplants (HR, 0.76; P = .05), transplant-related mortality (HR, 1.91; P = .003) and overall mortality (HR, 1.34; P = .032) were higher than with bone marrow transplants. The 8-year probability of overall survival after transplantation of bone marrow was 47% compared with 42% after peripheral blood. The 8-year probability of leukemia-free survival was 40% after transplantation of bone marrow and peripheral blood. Lower relapse after transplantation of peripheral blood negated the survival advantage after transplantation of bone marrow. The observed higher acute and chronic GVHD seen with peripheral blood suggest cautious use of this graft in children and adolescents with acute leukemia.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Keywords:  Acute lymphoblastic leukemia (ALL); Acute myeloid leukemia (AML); Children; Graft-versus-host disease (GVHD); Peripheral blood

Mesh:

Year:  2018        PMID: 30142417      PMCID: PMC6286246          DOI: 10.1016/j.bbmt.2018.08.010

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  16 in total

1.  Testing for centre effects in multi-centre survival studies: a Monte Carlo comparison of fixed and random effects tests.

Authors:  P K Andersen; J P Klein; M J Zhang
Journal:  Stat Med       Date:  1999-06-30       Impact factor: 2.373

2.  Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: a report from the Bone Marrow Transplant Survivor Study.

Authors:  Christopher J Fraser; Smita Bhatia; Kirsten Ness; Andrea Carter; Liton Francisco; Mukta Arora; Pablo Parker; Stephen Forman; Daniel Weisdorf; James G Gurney; K Scott Baker
Journal:  Blood       Date:  2006-06-20       Impact factor: 22.113

3.  Effect of stem cell source on outcomes after unrelated donor transplantation in severe aplastic anemia.

Authors:  Mary Eapen; Jennifer Le Rademacher; Joseph H Antin; Richard E Champlin; Jeanette Carreras; Joseph Fay; Jakob R Passweg; Jakub Tolar; Mary M Horowitz; Judith C W Marsh; H Joachim Deeg
Journal:  Blood       Date:  2011-06-15       Impact factor: 22.113

4.  Long-term survival after transplantation of unrelated donor peripheral blood or bone marrow hematopoietic cells for hematologic malignancy.

Authors:  Mary Eapen; Brent R Logan; Fredrick R Appelbaum; Joseph H Antin; Claudio Anasetti; Daniel R Couriel; Junfang Chen; Richard T Maziarz; Philip L McCarthy; Ryotaro Nakamura; Voravit Ratanatharathorn; Ravi Vij; Richard E Champlin
Journal:  Biol Blood Marrow Transplant       Date:  2014-09-22       Impact factor: 5.742

5.  Graft failure in the modern era of allogeneic hematopoietic SCT.

Authors:  R Olsson; M Remberger; M Schaffer; D M Berggren; B-M Svahn; J Mattsson; O Ringden
Journal:  Bone Marrow Transplant       Date:  2012-12-10       Impact factor: 5.483

6.  Burden of morbidity in 10+ year survivors of hematopoietic cell transplantation: report from the bone marrow transplantation survivor study.

Authors:  Can-Lan Sun; John H Kersey; Liton Francisco; Saro H Armenian; K Scott Baker; Daniel J Weisdorf; Stephen J Forman; Smita Bhatia
Journal:  Biol Blood Marrow Transplant       Date:  2013-04-10       Impact factor: 5.742

7.  Peripheral-blood stem cells versus bone marrow from unrelated donors.

Authors:  Claudio Anasetti; Brent R Logan; Stephanie J Lee; Edmund K Waller; Daniel J Weisdorf; John R Wingard; Corey S Cutler; Peter Westervelt; Ann Woolfrey; Stephen Couban; Gerhard Ehninger; Laura Johnston; Richard T Maziarz; Michael A Pulsipher; David L Porter; Shin Mineishi; John M McCarty; Shakila P Khan; Paolo Anderlini; William I Bensinger; Susan F Leitman; Scott D Rowley; Christopher Bredeson; Shelly L Carter; Mary M Horowitz; Dennis L Confer
Journal:  N Engl J Med       Date:  2012-10-18       Impact factor: 91.245

8.  Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival.

Authors:  Mary Eapen; Brent R Logan; Dennis L Confer; Michael Haagenson; John E Wagner; Daniel J Weisdorf; John R Wingard; Scott D Rowley; David Stroncek; Adrian P Gee; Mary M Horowitz; Claudio Anasetti
Journal:  Biol Blood Marrow Transplant       Date:  2007-10-10       Impact factor: 5.742

Review 9.  1994 Consensus Conference on Acute GVHD Grading.

Authors:  D Przepiorka; D Weisdorf; P Martin; H G Klingemann; P Beatty; J Hows; E D Thomas
Journal:  Bone Marrow Transplant       Date:  1995-06       Impact factor: 5.483

10.  Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients.

Authors:  H M Shulman; K M Sullivan; P L Weiden; G B McDonald; G E Striker; G E Sale; R Hackman; M S Tsoi; R Storb; E D Thomas
Journal:  Am J Med       Date:  1980-08       Impact factor: 4.965

View more
  1 in total

1.  Thrombotic Microangiopathy: Multi-Institutional Review of Pediatric Patients Who Underwent HSCT.

Authors:  Archana Ramgopal; Shiva Sridar; Jignesh Dalal; Ramasubramanian Kalpatthi
Journal:  J Pers Med       Date:  2021-05-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.